Bristol Myers Squibb (NYSE:BMY) Releases FY 2025 Earnings Guidance

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Bristol Myers Squibb (NYSE:BMY - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 6.350-6.650 for the period, compared to the consensus EPS estimate of 6.762. The company issued revenue guidance of $46.5 billion-$47.5 billion, compared to the consensus revenue estimate of $46.2 billion.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on BMY. Wall Street Zen cut Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $55.00 target price on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $55.00 target price (down previously from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. UBS Group reduced their target price on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research note on Friday, April 11th. Finally, Piper Sandler began coverage on Bristol Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price on the stock. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $57.33.

Bristol Myers Squibb Trading Up 2.6%

Shares of BMY traded up $1.16 during trading hours on Monday, hitting $45.39. The stock had a trading volume of 14,656,292 shares, compared to its average volume of 13,625,376. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The firm has a market cap of $92.39 billion, a P/E ratio of 18.30, a P/E/G ratio of 2.33 and a beta of 0.36. The company's fifty day simple moving average is $47.51 and its 200 day simple moving average is $52.23. Bristol Myers Squibb has a 12-month low of $42.96 and a 12-month high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%. The firm had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. During the same period in the prior year, the firm earned $2.07 EPS. The firm's quarterly revenue was up .6% compared to the same quarter last year. Equities research analysts forecast that Bristol Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.5%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is currently 100.00%.

Institutional Trading of Bristol Myers Squibb

A hedge fund recently raised its stake in Bristol Myers Squibb stock. Brighton Jones LLC boosted its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 33.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,728 shares of the biopharmaceutical company's stock after purchasing an additional 4,935 shares during the period. Brighton Jones LLC's holdings in Bristol Myers Squibb were worth $1,116,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.